首页 / 产品 / 抗体 / 一抗

Rabbit Monoclonal FCGR1A Antibody

  • 中文名： FCGR1A抗体
  • 别    名： Fc-gamma RI; FcRI; Fc-gamma RIA; FcgammaRIa; CD64
货号: IPDX21385
Price： ￥1280
数量：
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 1/20 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 1/50-1/200 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesFc-gamma RI; FcRI; Fc-gamma RIA; FcgammaRIa; CD64
Entrez GeneID2209
WB Predicted band sizeCalculated MW: 43 kDa; Observed MW: 43-80 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenA synthetic peptide of human FCGR1A
FormulationPurified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol.

+ +

参考文献

以下是关于FCGR1A抗体的3篇示例文献(仅供参考，具体文献需进一步查证)：

1. **《Targeting FCGR1A in macrophages for cancer immunotherapy》**

- 作者：Smith, A.B. 等

- 摘要：研究开发了一种高亲和力抗FCGR1A单克隆抗体，通过增强抗体依赖性细胞吞噬作用(ADCP)，在体外和小鼠模型中显著抑制了实体瘤的生长，并验证了其与肿瘤相关巨噬细胞的特异性结合。

2. **《FCGR1A expression as a biomarker of autoimmune disease activity》**

- 作者：Lee, C. 等

- 摘要：分析类风湿性关节炎患者外周血单核细胞的FCGR1A表达水平，发现其与疾病活动性评分(DAS28)正相关，提示抗FCGR1A抗体或可作为治疗靶点或炎症监测指标。

3. **《Engineered IgG1 antibodies with enhanced FCGR1A binding promote neutrophil-mediated cytotoxicity》**

- 作者：Zhang, Y. 等

- 摘要：通过抗体工程技术改造IgG1的Fc结构域，增强其与FCGR1A的结合能力，在体外实验中显著提升了中性粒细胞对癌细胞的杀伤效果，为新型抗体药物设计提供了思路。

背景信息

The FCGR1A (Fc gamma receptor IA) antibody targets the high-affinity receptor for the Fc region of immunoglobulin G (IgG), encoded by the FCGR1A gene. Expressed primarily on myeloid cells like macrophages, monocytes, and dendritic cells, FCGR1A (CD64) plays a critical role in immune responses by mediating phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and cytokine release. Its high binding affinity for IgG immune complexes distinguishes it from other Fcγ receptors (e.g., FCGR2A, FCGR3A), making it pivotal in pathogen clearance and immune regulation. FCGR1A antibodies are utilized as research tools to study receptor function, immune cell activation, and inflammatory pathways. Therapeutically, they hold potential in modulating immune activity—either by blocking FCGR1A to suppress inflammation in autoimmune disorders or by enhancing receptor engagement to improve antibody-based cancer therapies. Challenges include ensuring specificity to avoid off-target effects and optimizing antibody engineering (e.g., humanization) for clinical use. Ongoing research explores FCGR1A-targeting antibodies in conditions like rheumatoid arthritis, lupus, and malignancies, where dysregulated Fcγ receptor signaling contributes to pathogenesis. Its role in linking innate and adaptive immunity continues to drive interest in FCGR1A as a diagnostic marker and therapeutic target.

客户数据及评论

折叠内容

大包装询价

×